Article

Mmarketwatch.com on 2019-09-03 23:33

Puma Biotech stock surges on FDA cancer drug designation

Puma Biotechnology Inc. shares rallied in the extended session Tuesday after the drug developer said the Food and Drug Administration granted its cancer...

Related news

MPuma Biotech stock surges 50% on favorable FDA release for breast cancer drug marketwatch.com
MCalithera Biosciences stock surges on news of FDA fast track designation for kidney cancer treatment marketwatch.com
San Francisco , Southern States
BPuma Stock Jumps as Biotech Gets Good News From the FDA barrons.com
SA biotech gets FDA orphan drug designation bizjournals.com
Portland biotech company gains FDA Fast Track designation bizjournals.com
Fast Track , Portland
MPuma Biotech shares jump on breast cancer study, FDA application marketwatch.com
MGenprex's stock rallies on FDA fast-track designation marketwatch.com
MPuma Biotech shares slide on secondary stock offering marketwatch.com
Boulder biotech firm gets 'Breakthrough Device' FDA designation for cancer gene test bizjournals.com
Boulder
MKrystal Biotech shares up 27% after company's skin drug receives expedited review designation from FDA marketwatch.com
Phase 2
MTeva stock surges 7% after FDA approves migraine medication marketwatch.com
Peninsula biotech surges as FDA lifts hold on growth hormone study bizjournals.com
Canada , Western Europe , United States , San Francisco Bay Area , Menlo Park
MAlnylam Pharma stock rises 1.5% after FDA gives drug 'breakthrough therapy' designation marketwatch.com
MClovis Oncology stock rises 10% premarket after 'breakthrough' designation from FDA marketwatch.com
Clovis
MHeron stock up 4.3% after opioid alternative granted priority review designation from FDA marketwatch.com
Phase 2 , Quart
MUPDATE: Pluristem stock jumps 21% premarket after FDA grants CLI treatment fast-track designation marketwatch.com
Europe , Israel
MAkari Therapeutics' stock rockets on heavy volume after FDA grants nomacopan 'Fast Track' designation marketwatch.com
Fast Track
MCerecor stock soars 17% premarket after FDA grants fast-track designation to treatment for rare disorder marketwatch.com
Rockville
FDA rejects NRx's breakthrough designation bid for experimental Covid-19 therapy; stock price falls bizjournals.com
MEdesa Biotech stock rockets 140% after FDA gives go-ahead to early-stage trial marketwatch.com